Capitol Perspectives

The Capitol Perspectives column is written by John McManus, president and founder of The McManus Group, a consulting firm specializing in strategic policy and political counsel and advocacy for healthcare clients with issues before Congress and the administration. Prior to founding his firm, McManus served Chairman Bill Thomas as the staff director of the Ways and Means Health Subcommittee, where he led the policy development, negotiations, and drafting of the Medicare Prescription Drug, Improvement and Modernization Act of 2003. Before working for Chairman Thomas, McManus worked for Eli Lilly & Company as a senior associate and for the Maryland House of Delegates as a research analyst.
  • Path Forward On Obamacare Replacement?
    Path Forward On Obamacare Replacement?

    After the House of Representatives passed The American Health Care Act — the bill that would replace Obamacare — by a razor-thin margin, consideration moved to the Senate, where Republicans have only two votes to spare to secure passage.

  • Drug Costs Moderating, But Growing Copays Fuel Ire

    At a Stanford University conference last week, Office of Management and Budget (OMB) Director Mick Mulvaney said President Trump keeps asking him what he is doing to address the high cost of pharmaceuticals.

  • Provider Consolidation Raising Costs And Undermining Competition

    As Republicans attempt to recover from their face-plant on repealing and replacing Obamacare, policymakers are grappling with how to address the growing problem of healthcare provider consolidation, which appears to be raising costs and undermining competition.

  • Repeal & Replace Confronts Trump’s Base

    To understand the political peril Republicans confront in their effort to repeal and replace Obamacare, it is worth noting that many of the areas that gained the most coverage from Obamacare are the working-class districts carried by President Trump with the largest margins.

  • Pharmaceuticals Escape The Knife As GOP Mulls Medicaid Reform

    After bracing for the worst, pharmaceutical executives emerged from a White House meeting with newly installed President Donald J. Trump relatively unscathed. But they soon concluded that his ever-roving spotlight would be back on them in a matter of time.

  • Trump Targets The Pharmaceutical Industry

    Our new President seemed to criticize recent inversions, but more importantly vowed to go after the industry: “Our drug industry has been disastrous.

  • Risks And Rewards Of Repeal And Replace

    The Republican sweep in the 2016 elections hands the enormous power of the Center for Medicare and Medicaid Innovation (CMMI) to the Trump administration. What to do with this power?

  • Washington Outlook For 2017: Trump Takes The Helm

    The stunning Trump victory and the Republican hold in the Senate, giving the GOP full control over the executive and legislative branches, provides some breathing space for a pharmaceutical industry that increasingly felt under siege.

  • Leaked Emails, Physician Reg Signal Risks For Rx Industry

    As the most bizarre and unpredictable election season draws to a close, scrutiny is turning to wikileaked emails among senior officials in the Clinton campaign licking their chops to take on the pharmaceutical industry, and healthcare policymaking by the executive branch.

  • Congress’ Abdication Of Authority Of Medicare To The Executive

    Six years after the enactment of the Affordable Care Act (ACA), policymakers are just beginning to appreciate a little-known provision that essentially outsources Congress’ authority over Medicare to the executive branch.

  • Rx Industry Vulnerable On Generic Delay In Fall

    There is growing chatter among congressional aides that the pharma industry should ante up some resources to help address some yet-unresolved healthcare issues.

More From Capitol Perspectives

LIFE SCIENCE EVENTS

Alice June 26 - 28, 2017
Bangkok, CA
FDA GMP Inspections – Proven Preparation & Survival Techniques June 27, 2017
1pm-2:30pm EDT, Online Training
Price:  $299 - Includes Bonus Handouts!
Biomanufacturing Strategy Meeting USA 2017 June 27, 2017
HILTON BOSTON LOGAN AIRPORT, MA
DCAT Sharp Sourcing 2017 June 27, 2017
New Brunswick, NJ
Rational Combinations 360° June 28 - 29, 2017
New York, NY
Clinical Trial Supply Chain Strategy Meeting USA 2017 June 28, 2017
HILTON BOSTON LOGAN AIRPORT, USA, MA
Rational Combinations 360° June 28 - 29, 2017
New York, NY
How To Establish The Number of Runs Required For Process Validation June 28, 2017
1:00 - 2:00 PM EDT, Online Training
Duration:  60 Minutes
Price:  $299 - Includes Bonus Handouts!
12th Annual Conference on Nephrology & Urology 2017 July 6 - 7, 2017
Kuala Lumpur, FL
12th Annual Conference on Nephrology & Urology 2017 July 6 - 7, 2017
Kuala Lumpur, VT
Certified Copies and ALCOA-C: Essentials Post ICH GCP E6 (R2) Addendum July 10, 2017
11:00am- 12:00pm EDT, Online Training
Duration:  60 Minutes
Price:  $299 - Includes Bonus Handouts!
CRO Oversight Post ICH GCP E6 (R2) Addendum July 10, 2017
11:00am- 12:00pm EDT, Online Training
Duration:  60 Minutes
Price:  $299 - Includes Bonus Handouts!
Conducting an Effective GCP Audit of a CRO-Managed Ongoing Study: Tips and Suggestions July 11, 2017
1:00 - 2:30 PM EDT, Online Training
Duration:  90 Minutes
Price:  $299 - Includes Bonus Handouts!
Manufacturing & Laboratory Equipment Qualification – Ensuring Bullet-Proof Results July 12, 2017
1:00 - 2:00 PM EDT, Online Training
Duration:  60 Minutes
Price:  $299 - Includes Bonus Handouts!
David Richard July 17 - 18, 2017
Lisbon, AL
Daniel Smith July 20 - 22, 2017
Melbourne, ME
Clinical Study Requirements – Understanding Differences Between the US and EU July 25, 2017
1pm-2:30pm EST, Online Training
Price:  $299 - Includes Bonus Handouts!
NGS and Clinical Applications Congress: USA July 25 - 26, 2017
Philadelphia, PA